NCT04003103View on ClinicalTrials.gov

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

PHASE2CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

March 18, 2022

Study Completion Date

November 24, 2022

Conditions
HIV-1 Infection
Interventions
DRUG

Islatravir

Islatravir 30 mg capsules taken by mouth.

DRUG

Placebo

Placebo capsules taken by mouth.

Trial Locations (9)

2092

Clinical HIV Research Unit CHRU ( Site 0014), Johannesburg

7750

Emavundleni Vaccine Centre ( Site 0011), Cape Town

9301

JOSHA Research ( Site 0015), Bloemfontein

15213

Magee Womens Research Institute ( Site 0001), Pittsburgh

21287

Johns Hopkins School of Medicine - Drug Development Unit ( Site 0002), Baltimore

33024

Research Centers of America, LLC ( Site 0007), Hollywood

68502

Celerion, Inc. ( Site 0006), Lincoln

3109601

Rambam Medical Center ( Site 0017), Haifa

9112001

Hadassah Ein Karem Jerusalem ( Site 0016), Jerusalem

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04003103 - Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) | Biotech Hunter | Biotech Hunter